METHODS

Clinical Data:
• 7 controlled clinical trials following the same study protocol
• n = 184 patients with OGIB and previous negative gastroscopy and negative colonoscopy (examinations, transfusions and hospitalizations) . It is assumed that these costs vary with the examination sequence, i.e. an early examination after onset of symptoms without prior diagnostic (low disease prevalence) might cause more further examination cycles compared to an examination at a later stage in the diagnostic path (high disease prevalence).
FP: treatment of every second patient with therapeutic PE (4/9 of patients) or therapeutic angiography (4/9 of patients) or intraoperative endoscopy (1/9 of patients).
• Incremental Cost-Effectiveness (ICE) of PE vs. CE varies depending on the disease prevalence in the patient populations (Fig. 1 ).
• Cost per additional correctly diagnosed patient less than with PE, i.e. cost saving for health care payer, in all countries if the prevalence exceeds 10%.
• Greatest savings observed for the CH.
Isocontour graphs -results of probabilistic sensitivity analyses -demonstrate high consistency within 10,000 analyses (Figure 2 • Incremental cost-effectiveness (ICE) and isocontour graphs
Cost Data:
• Procedure cost of CE and PE • Cost of diagnostic failure:
-due to false positive diagnosis (FP) -due to false negative diagnosis (FN)
• For FP cost an assumption of unnecessary treatment was made
• For FN cost diagnostic procedures performed two years prior to study start were considered and allocated according prevalences in the model
